-
Barinthus Bio announces data from phase 1b/2 APOLLO clinical trial of VTP─200
20 Apr 2024 08:14 GMT
… -stage biopharmaceutical company developing novel T cell immunotherapeutic … VTP-200. The trial was also designed to … developed as a potential non-invasive treatment for persistent high-risk HPV … of human papillomavirus DNA. Persistent genital HPV infection is …
-
11 Million Fewer HPV Vaccines Available in 2024
20 Apr 2024 03:23 GMT
… and less developed cervical cancer screening and treatment programs.
On … broader protection against multiple HPV types.
Separately, the … additional VLPs for expanded HPV-type coverage.
This … S., HPV vaccines remain available at clinics and pharmacies in …
-
Histogen files for bankruptcy; Barinthus Bio shares Ph1b/2 data for HPV treatment
19 Apr 2024 15:56 GMT
… touts Ph1b/2 HPV data: The company’s … a trial of 108 women with high-risk HPV-associated … low-grade cervical lesions. The group with the highest treatment … dose achieved a 60% high-risk HPV clearance …
-
Barinthus’ HPV therapy meets primary endpoint in Phase I/II trial
19 Apr 2024 09:52 GMT
… 47;II APOLLO trial for its human papillomavirus (HPV) treatment, VTP-200 … given that the trial was not powered … development for treating precancerous cervical lesions is Asieris Pharmaceuticals’ drug- … US Food and Drug Administration (FDA) approved vaccine for …
-
Barinthus Bio Announces Topline Data from Phase 1b/2 APOLLO Trial of VTP-200 in Persistent High-Risk Human Papillomavirus (HPV) Infections
18 Apr 2024 20:10 GMT
… given that the trial was not powered … developed as a potential non-invasive treatment for persistent high-risk HPV … persistent high-risk human papillomavirus (HPV); VTP-1000, an … immunotherapeutic candidate designed to treat recurrent prostate cancer. …
-
Pharma Pulse 4/19/24: The Real Cost of State Drug Importation Programs, Millions in Africa Will Miss HPV Shots After Merck Production Problem & more
19 Apr 2024 10:40 GMT
… of State Drug Importation Programs? Patient Safety
Importing drugs from … in Africa Will Miss HPV Shots After Merck Production … confidence in their diagnostic and treatment determinations.
LogiPharma on LinkedIn: … us to share in Pharma Pulse? Reach out to …
-
Empowering women to stand up against HPV and Cervical Cancer
19 Apr 2024 05:38 GMT
… cancer is the human papillomavirus (HPV), a virus commonly spread … chances of developing this disease
Immunization against HPV.
HPV and … with cervical disease receive treatment (90% with pre-cancer … been exposed to HPV.
By understanding HPV and cervical cancer …
-
Nykode Therapeutics Initiates Phase 2 Trial of VB10.16 in Second Line HPV16-Positive Cervical Cancer
19 Apr 2024 05:00 GMT
… “Initiating the VB10.16 trial for HPV16-positive cervical … candidate in development for the treatment of human papillomavirus type 16 … are caused by human papillomavirus (HPV) infection and HPV16 … to work directly with pharmaceutical organizations and operate …
-
Rigosertib sodium by Traws Pharma for Epidermolysis Bullosa: Likelihood of Approval
19 Apr 2024 02:08 GMT
… Renal Cell Carcinoma, Human Papillomavirus (HPV) Associated Cancer, Esophageal … cell cancer.
Traws Pharma overview
Onconova Therapeutics ( … develops small molecule drug candidates for the treatment of cancer. The company’s drug … is used to treat the effects of …
-
Health workers to visit schools to jab over 3,000 girls, who missed second HPV vaccine dose
19 Apr 2024 01:33 GMT
… first dose of the human papillomavirus (HPV) vaccine did not show up … most common cancer in the developing world and a major … vaccine.
Experts say early treatment prevents up to 80 percent … proposed a budget for nationwide HPV vaccination campaigns in 2024.
…